The UK and US have secured a landmark trade agreement that will keep zero duties on UK drug exports going into the US market.
Key Provisions of the Pact
As part of the deal, the UK has committed to boost expenditure on drugs through the NHS. This pledge ensures that import taxes on these crucial goods will remain at zero for a duration of three years.
This agreement follows recent statements to significantly raise tariffs on branded pharmaceutical imports, with increases discussed as high as one hundred percent.
"This deal between the United Kingdom reinforces the global environment for new treatments and brings much-needed balance to U.S.–U.K. drug exports," an announcement noted.
Commercial Importance
Medicines are one of the UK's largest export categories to the US, which is clearly the primary market for major companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months to the end of the third quarter, the UK exported medicines worth £11.1bn to the US. This amount represented nearly one-fifth of British export trade in that span.
"This deal safeguards jobs, boosts funding and facilitates the UK to become a worldwide center for biotech and pharma," a government official commented.
Specific NHS Changes
The deal entails several key pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise overall NHS spending on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds exceeded twenty percent.
Broader Context
This agreement comes amid a protracted row between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
This friction were exacerbated by arguments that American customers were paying a premium for the same drugs than consumers in the other developed nations.
Over the last 18 months, several significant drug company projects in the UK have been paused or abandoned, while substantial expansions have been directed toward US facilities.
A senior figure stated that the NHS needed to spend more on treatments, noting that its expenditure on drugs had shrunk as a percentage of its resources over the past decade.
